布地格福与布地奈德福莫特罗粉对COPD缓解期患者肺功能、运动耐力的影响对比

摘要 目的：探讨布地格福与布地奈德福莫特罗粉对慢性阻塞性肺疾病（COPD）缓解期患者肺功能、运动耐力的影响。方法：选取2020年1月至2022年12月本院收治的300例COPD缓解期患者，将其随机分为A组（n=150）和B组（n=150），A组予以布地格福吸入治疗，B组予以布地奈德莫特罗粉吸入治疗。连续治疗3个月后，比较两组疗效及用药安全性；比较两组肺功能、血气水平、运动耐力和生活质量、炎症指标变化。结果：连续治疗3个月后，A组治疗总有效率为96.00 %，高于对照组的90.00 %（P＜0.05）；治疗后两组第1 s用力呼气容积（FEV₁）、FEV₁/用力肺活量、FEV₁占预计值百分数、血氧分压、6 min步行距离较治疗前均有提升，且A组高于B组（P＜0.05）；治疗后两组残气容积/肺总量、二氧化碳分压、白细胞介素-17、基质金属蛋白酶-9、圣乔治呼吸问卷评分较治疗前均有降低，且A组低于B组（P＜0.05）；治疗期间两组均未发生严重的不良反应（P＞0.05）。结论：相较于布地奈德福莫特罗，布地格福对COPD缓解期的治疗效果更佳，能有效减低气道炎症损伤，改善其肺功能及血气水平，提升患者运动耐力及生活质量。

Comparison on the Effects of Budesonide Glycopyrronium Bromide and Budesonide Formoterol on Pulmonary Function and Exercise Tolerance in Patients with COPD during Remission

ABSTRACT Objective: To explore the effects of budesonide glycopyrronium bromide and budesonide formoterol on pulmonary function and exercise tolerance in patients with chronic obstructive pulmonary disease (COPD) during remission. Methods: A total of 300 patients with COPD during remission in the hospital were enrolled and randomly divided into group A (n=150) and group B (n=150) between January 2020 and December 2022. The group A was given budesonide glycopyrronium bromide, while group B was given budesonide formoterol for inhalation therapy. After 3 months of continuous treatment, curative effect and medication safety, changes of pulmonary function, blood gas level, exercise tolerance, quality of life and inflammatory indexes were compared between the two groups. Results: After 3 months of continuous treatment, total response rate of treatment in group A was higher than that in control group (96.00% vs 90.00%, P<0.05). After treatment, forced expiratory volume in 1 second (FEV₁), FEV₁/forced vital capacity, FEV₁ as percentage of predicted value, partial pressure of oxygen and 6 min walking distance in both groups were increased, which were higher in group A than group B (P<0.05), while residual volume/total lung capacity, partial pressure of carbon dioxide, interleukin-17, matrix metalloproteinase-9 and score of St. George''s Respiratory Questionnaire were decreased, which were lower in group A than group B (P<0.05). There were no serious adverse reactions in either group during treatment (P>0.05). Conclusion: Compared with budesonide formoterol, budesonide glycopyrronium bromide has better curative effect, which can effectively reduce airway inflammation injury, improve pulmonary function, blood gas level, exercise tolerance and quality of life in patients with COPD during remission.